Position in PHVS
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$6,930,489
+$6,013,651 QoQ
Shares Held
200,419
+311.0% QoQ
Ownership
0.285%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#43
of 124 holders
Holding Since
Dec 2022
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PHVS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Walleye Capital LLC holds $328,656,270 across 126 Biotechnology names. PHVS ranks #13 (2.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
126,005 | $33,608,053 | |
| 2 | CYTK |
Cytokinetics Inc
|
239,728 | $20,422,428 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
288,233 | $16,492,692 | |
| 4 | IDYA |
IDEAYA Biosciences, Inc.
|
386,183 | $14,393,040 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
22,596 | $14,089,509 | |
| 6 | RARE |
Ultragenyx Pharmaceutical Inc.
|
334,854 | $11,180,775 | |
| 7 | TYRA |
Tyra Biosciences, Inc.
|
347,898 | $11,111,862 | |
| 8 | BCAX |
Bicara Therapeutics Inc.
|
353,226 | $10,487,279 |
All Filings in PHVS
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,930,489 | 200,419 | Shares | Sole | 2026-08-03 | |
| 2024-06-30 | $916,838 | 48,768 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $2,245,876 | 97,182 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $2,184,253 | 77,870 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $1,690,824 | 81,017 | Shares | Sole | 2023-11-21 | |
| 2023-06-30 | $1,064,735 | 70,326 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $885,606 | 109,945 | Shares | Sole | 2023-05-15 | |
| 2022-12-31 | $1,702,451 | 151,329 | Shares | Sole | 2023-02-14 | |
| No filing history on record for this holder in this stock. | ||||||